On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...